Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 14, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 14, 2026; holds 50,013 after (Direct).
  • Open-market sale: disposed of 840 Common Stock at $524.15 ($440,284) on July 14, 2026; holds 49,173 after (Direct).
  • Open-market sale: disposed of 1,468 Common Stock at $525.16 ($770,940) on July 14, 2026; holds 47,705 after (Direct).
  • Open-market sale: disposed of 3,492 Common Stock at $526.13 ($1,837,255) on July 14, 2026; holds 44,213 after (Direct).
  • Open-market sale: disposed of 1,220 Common Stock at $527.06 ($643,010) on July 14, 2026; holds 42,993 after (Direct).
  • Open-market sale: disposed of 660 Common Stock at $528.13 ($348,569) on July 14, 2026; holds 42,333 after (Direct).
  • Open-market sale: disposed of 959 Common Stock at $529.21 ($507,512) on July 14, 2026; holds 41,374 after (Direct).
  • Open-market sale: disposed of 554 Common Stock at $530.67 ($293,993) on July 14, 2026; holds 40,820 after (Direct).
  • Open-market sale: disposed of 107 Common Stock at $531.08 ($56,826) on July 14, 2026; holds 40,713 after (Direct).
  • Open-market sale: disposed of 200 Common Stock at $532.60 ($106,520) on July 14, 2026; holds 40,513 after (Direct).
  • Option exercise/conversion: disposed of 9,500 Stock Option on July 14, 2026; holds 1,718 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,004,909 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-14Option exercise/conversionCommon Stock9,500$135$1.3M50,013
2026-07-14Open-market saleCommon Stock840$524$440.3K49,173
2026-07-14Open-market saleCommon Stock1,468$525$770.9K47,705
2026-07-14Open-market saleCommon Stock3,492$526$1.8M44,213
2026-07-14Open-market saleCommon Stock1,220$527$643.0K42,993
2026-07-14Open-market saleCommon Stock660$528$348.6K42,333
2026-07-14Open-market saleCommon Stock959$529$507.5K41,374
2026-07-14Open-market saleCommon Stock554$531$294.0K40,820
2026-07-14Open-market saleCommon Stock107$531$56.8K40,713
2026-07-14Open-market saleCommon Stock200$533$106.5K40,513
2026-07-14Option exercise/conversionStock Option9,500——1,718

Key Dates

DateDescription
2026-07-14Option exercise/conversion (9,500 shares)
2026-07-14Open-market sale (840 shares)
2026-07-14Open-market sale (1,468 shares)
2026-07-14Open-market sale (3,492 shares)
2026-07-14Open-market sale (1,220 shares)
2026-07-14Open-market sale (660 shares)
2026-07-14Open-market sale (959 shares)
2026-07-14Open-market sale (554 shares)
2026-07-14Open-market sale (107 shares)
2026-07-14Open-market sale (200 shares)
2026-07-14Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.